173 related articles for article (PubMed ID: 1451237)
1. Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
Bishop FE; Dive C; Freeman S; Gescher A
Cancer Chemother Pharmacol; 1992; 31(2):85-92. PubMed ID: 1451237
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
Dive C; Watson JV; Workman P
Cancer Res; 1991 Feb; 51(3):799-806. PubMed ID: 1988120
[TBL] [Abstract][Full Text] [Related]
3. The degradation of platelet-activating factor and related lipids: susceptibility to phospholipases C and D.
Wilcox RW; Wykle RL; Schmitt JD; Daniel LW
Lipids; 1987 Nov; 22(11):800-7. PubMed ID: 3444369
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antitumoral activity of alkylphosphonates.
Ries UJ; Fleer EA; Breiser A; Unger C; Stekar J; Fenneberg K; Eibl H
Eur J Cancer; 1992; 29A(1):96-101. PubMed ID: 1445752
[TBL] [Abstract][Full Text] [Related]
5. Alkyl phosphocholines: toxicity and anticancer properties.
Muschiol C; Berger MR; Schuler B; Scherf HR; Garzon FT; Zeller WJ; Unger C; Eibl HJ; Schmähl D
Lipids; 1987 Nov; 22(11):930-4. PubMed ID: 3444388
[TBL] [Abstract][Full Text] [Related]
6. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action.
Lohmeyer M; Workman P
Biochem Pharmacol; 1992 Aug; 44(4):819-23. PubMed ID: 1510728
[TBL] [Abstract][Full Text] [Related]
7. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
Fleer EA; Berkovic D; Grunwald U; Hiddemann W
Eur J Cancer; 1996 Mar; 32A(3):506-11. PubMed ID: 8814699
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of hexadecylphosphocholine in neoplastic cell lines including drug-resistant sublines in vitro.
Danhauser-Riedl S; Himmelmann A; Steinhauser G; Busch R; Vogler WR; Rastetter J; Berdel WE
J Lipid Mediat; 1990; 2(5):271-80. PubMed ID: 2133272
[TBL] [Abstract][Full Text] [Related]
9. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe.
Lohmeyer M; Workman P
Biochem Pharmacol; 1993 Jan; 45(1):77-86. PubMed ID: 8424826
[TBL] [Abstract][Full Text] [Related]
10. The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D.
Wieder T; Zhang Z; Geilen CC; Orfanos CE; Giuliano AE; Cabot MC
Cancer Lett; 1996 Feb; 100(1-2):71-9. PubMed ID: 8620456
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.
Powis G; Seewald MJ; Gratas C; Melder D; Riebow J; Modest EJ
Cancer Res; 1992 May; 52(10):2835-40. PubMed ID: 1316230
[TBL] [Abstract][Full Text] [Related]
12. Hexadecylphosphocholine differs from conventional cytostatic agents.
Berger MR; Betsch B; Gebelein M; Amtmann E; Heyl P; Scherf HR
J Cancer Res Clin Oncol; 1993; 119(9):541-8. PubMed ID: 8392075
[TBL] [Abstract][Full Text] [Related]
13. Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834.
Lazenby CM; Thompson MG; Hickman JA
Cancer Res; 1990 Jun; 50(11):3327-30. PubMed ID: 2334926
[TBL] [Abstract][Full Text] [Related]
14. Effects of the ether phospholipid AMG-PC on mast cells are similar to that of the ether lipid AMG but different from that of the analogue hexadecylphosphocholine.
Grosman N
Immunopharmacology; 1991; 22(1):39-47. PubMed ID: 1791141
[TBL] [Abstract][Full Text] [Related]
15. Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.
Lohmeyer M; Workman P
Br J Cancer; 1995 Aug; 72(2):277-86. PubMed ID: 7640206
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives.
Papazafiri P; Avlonitis N; Angelou P; Calogeropoulou T; Koufaki M; Scoulica E; Fragiadaki I
Cancer Chemother Pharmacol; 2005 Sep; 56(3):261-70. PubMed ID: 15856232
[TBL] [Abstract][Full Text] [Related]
17. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
Magistrelli A; Villa P; Benfenati E; Modest EJ; Salmona M; Tacconi MT
Drug Metab Dispos; 1995 Jan; 23(1):113-8. PubMed ID: 7720513
[TBL] [Abstract][Full Text] [Related]
18. Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties.
Sobottka SB; Berger MR
Cancer Chemother Pharmacol; 1992; 30(5):385-93. PubMed ID: 1505077
[TBL] [Abstract][Full Text] [Related]
19. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis.
Katz-Brull R; Seger D; Rivenson-Segal D; Rushkin E; Degani H
Cancer Res; 2002 Apr; 62(7):1966-70. PubMed ID: 11929812
[TBL] [Abstract][Full Text] [Related]
20. Effects of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity.
Goppelt-Struebe M; Winter I
Cancer Chemother Pharmacol; 1995; 35(6):519-26. PubMed ID: 7882461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
